Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a popular platform reveals the hidden risks of online prescriptions.

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and ...